We found that the GLP-1RAs showed identified advantages in liver protection, especially in the replacement of insulin or sulfonylurea
They minimize systemic inflammation by many mechanisms: direct suppression of pro-inflammatory cytokine synthesis (TNF-, IL-6, IL-1), augmentation of anti-inflammatory mediators (IL-10, adiponectin), and alteration of immune cell morphologies
The limited treatment landscape has created significant interest in repurposing existing drugs, particularly glucagon-like peptide-1 (GLP-1) receptor agonists, which address multiple metabolic pathways implicated in fatty liver disease
Clinical studies, such as the STEP and SURMOUNT trials, show that the best results are achieved with consistent treatment over at least six months to one year
Rhythm Pharmaceuticals (RYTM) is also involved in peptidergic drugs for weight loss
This medication can lead to significant weight loss, particularly by reducing body fat